Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations

J Clin Oncol. 2010 Dec 1;28(34):e701-3. doi: 10.1200/JCO.2010.28.6260. Epub 2010 Sep 7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Base Sequence
  • Chemotherapy, Adjuvant / methods
  • Cholecystitis / complications
  • Cholecystitis / pathology
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • DNA Mutational Analysis
  • Female
  • Gefitinib
  • Genes, erbB-1*
  • Genetic Predisposition to Disease
  • Humans
  • Incidental Findings
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation
  • Neoplasm Staging
  • Pedigree
  • Pneumonectomy
  • Quinazolines / therapeutic use*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives
  • Vinorelbine

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Vinblastine
  • Cisplatin
  • Vinorelbine
  • Gefitinib